Objective: Endovascular interventions of the common (CFA) and deep (DFA) femoral arteries are becoming more common. However, there is very little published data for guidance. Our objective was to analyze practice patterns and outcomes from these interventions.
Percutaneous endovascular interventions (PVIs) for the management of peripheral arterial disease, in patients with both claudication and critical limb ischemia, have become more common and in many cases represent the first line of intervention. 1, 2 This is primarily the result of a favorable periprocedural risk profile compared with open surgery, with numerous reports demonstrating reduced perioperative mortality, morbidity, and length of stay (LOS). 3, 4 Given the high prevalence of severe comorbidities among those with peripheral arterial disease, vascular surgeons and other interventionalists have embraced PVIs. 3, 5, 6 Vascular specialists continue to push the limits of endovascular therapy despite lack of long-term or definitive data. This has extended to interventions on the common (CFA) and deep (DFA) femoral arteries. The role of endovascular therapy for atherosclerotic lesions in the CFA and DFA remains an area of controversy. Angioplasty of the CFA or DFA can risk dissection, potentially requiring stenting, the results of which are unclear. Flexion at the inguinal ligament may render the CFA an inhospitable environment for stents. 7, 8 Furthermore, the DFA is an important collateral vessel and is at risk of being covered if a stent is placed in the CFA. Finally, endarterectomy is commonly used to treat CFA and DFA occlusive disease and has both acceptable perioperative risk as well as excellent short-and longterm outcomes. [9] [10] [11] [12] Although traditionally endovascular interventions in the CFA and DFA were discouraged, recent reports have identified many vascular specialists' willingness to use PVI to treat disease at these locations. [13] [14] [15] [16] The benefit and risk profile of PVI in the CFA and DFA remains unclear as published literature is limited to single center studies with a small sample size and limited statistical analysis. [14] [15] [16] [17] [18] [19] [20] To obtain a contemporary "real world" view of PVI treatment of CFA and DFA, we queried the Vascular Quality Initiative (VQI) database to analyze practice patterns, procedural details, complications, and outcomes. Our goal was to have these data provide an evidence based framework for endovascular management of these arterial segments.
METHODS
The VQI started in 2010 as a national collaborative of regional quality groups and currently includes academic and community hospitals in North America with the goal of improving outcomes in patients with vascular disease. Clinical abstractors at these centers prospectively collect over 100 specific variables into distinct modules. [21] [22] [23] The
Boston University School of Medicine Institutional Review Board approved this study and informed consent was waived. We analyzed the PVI lower extremity module. We initially identified all cases where there was a CFA or DFA intervention. We then narrowed this cohort to cases where only the CFA was intervened on with or without concurrent DFA intervention for the multivariate and life table analysis. Perioperative outcomes were recorded for isolated DFA interventions, but further analysis was not performed because of low numbers. For the analysis of patency loss, we excluded technical failures. Case urgency was self-reported by the surgeon and center. Acute limb ischemia, emergent cases, aneurysmal indication, and bilateral interventions were excluded. For interventions, VQI only records two intervention types per segment. Technical result was self-reported by the surgeon and center as either successful, stenosis $30% or 10-mm gradient, or technical failure. Primary outcomes of interest were mortality, patency loss or death, reintervention or death, and amputation or death. Secondary perioperative outcomes included mortality at 30 days, access site hematoma, occlusion/stenosis, arterial dissection or perforation, and embolization. Survival, freedom from loss of patency or death, freedom from reintervention or death, and amputation-free survival were calculated.
Sample characteristics were described using counts and percentages for categorical variables and means and standard deviations for continuous variables. Rates of perioperative outcomes were evaluated and presented as counts and percentages. Kaplan-Meier product-limit estimates of the event-free survival were computed for primary outcomes: mortality, patency loss or death, reintervention or death, and amputation or death. Multivariable Cox proportional hazard models were used to assess association of patient characteristics with primary outcome measures. For each model, all clinically important characteristics (demographics, medical history, and comorbidities) were first included into the model, and then backward elimination procedure with 0.2-level to keep in the model was used to construct a more parsimonious model. The associations were expressed as adjusted hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). Data analyses were performed using SAS v 9.3 software (SAS Institute Inc, Cary, NC).
RESULTS
There were 5387 patients out of 72,842 (7.4%) with lower extremity PVI that had a CFA or DFA intervention. After excluding aneurysmal disease, bilateral interventions, emergent procedures, and those with concomitant aorta interventions, 3960 patients remained. Of these, 1296 had isolated CFA or DFA interventions. There were 1014 patients who had either an isolated CFA intervention (946) or a combined CFA and DFA intervention (68). There were 282 isolated DFA interventions. Average age of the isolated CFA 6 DFA cohort was 67.4 6 10.8 years, and 59% were male. The majority of patients were living at home preoperatively (98.3%; Table I ). The most common comorbidities were hypertension (92%), diabetes mellitus (46.7%), coronary artery disease (36.1%), and chronic obstructive pulmonary disease (COPD) (25%; Table I ). There were 36.6% of patients that had a prior lower extremity bypass, 49.3% that had a previous percutaneous intervention and 4.3% had a prior major amputation. In-person follow-up was 150.3 6 207.2 days. Mean follow-up for mortality was 745.1 6 555.6 days based on social security information. The follow-up patency was determined by palpable distal pulse (41% of cases), ankle-brachial index increase (10% of cases), one of the other methods including magnetic resonance angiography, duplex, computed tomography angiography or angiogram (48% of cases), and multiple modalities (1% of cases). The technique did not differ between intervention types (P ¼ .440).
There were 6.7% of patients who had a concurrent DFA intervention. Interventions on the CFA included angioplasty (76.6%), stent (25%), stent graft (2.3%), and atherectomy (19.4%). Cases were elective and urgent in 88.4% and 11.6% patients, respectively. Indications included claudication (67%), rest pain (16.3%), and tissue loss (16.7%). The procedure was technically successful in 91% of cases. In 4.8% of cases, residual stenosis was described, and technical failure rate was 4.1%. Patients were discharged on aspirin, a P2Y12 antagonist and statin in 80.6%, 63.9%, and 78.5% cases, respectively. Periprocedural complications included access site hematoma (5.2%), arterial dissection (2.9%), distal embolization (0.7%), access site stenosis/occlusion (0.5%), and arterial perforation (0.6%; Table II ). Thirty-day mortality was 1.6%. Postoperative LOS was 1.5 6 3.5 days. Mean inperson follow-up was 150.3 6 207.2 days. Mean followup for mortality was 745.1 6 555.6 days based on social security information.
Postprocedural survival was 92.9% at 1 year and 87.2% at 3 years by Kaplan-Meier analysis (Fig 1) . Patients had an 83% freedom from loss of patency or death at 1 year (Fig 2) , 85.3% reintervention-free survival (Fig 3) , and 93.5% amputation-free survival (Fig 4) 95% CI, .04-.59; P ¼ .006) were protective (Table VI) . In this sample, 21% of cases with reported PTA and stent had these procedures concurrently, majority of the cases (68%) had PTA alone, and only a small proportion of cases (11%) had stent alone. Analysis of patency loss over 1-year follow-up did not show significant difference across the three groups (log-rank P ¼ .144). Multivariable analysis showed no significant association of PTA and stent with patency loss. There were 282 isolated DFA interventions. Indications were claudication (45%), rest pain (25.9%), and tissue loss (29.1%). Treatment included angioplasty (80.9%), stenting (27.3%), stent graft (1.1%), and atherectomy (11.3%). Technical success rate was 94%. Periprocedural complications included access site hematoma (2.5%), arterial dissection (1.9%), distal embolization (0.7%), and arterial perforation (0.7%). Thirty-day mortality was 1.8%. Compared with isolated CFA interventions, these patients were less likely to be ambulatory (30.1% vs 16.4%; P < .001), have COPD (31.6% vs 25.1%; P ¼ .031), have a history of bypass (45.4% vs 36.6%; P ¼ .008), have a history of major amputation (9.9% vs 3.8%; P < .001), and have a history of PVIs (60.9% vs 49.4%; P < .001).
DISCUSSION
In the VQI, endovascular interventions in the CFA had low periprocedural complications and mortality. These procedures were mostly performed for claudication. Stent use was associated with high rates of reintervention and amputation. Several previously published studies evaluated the role of endovascular CFA intervention. These were limited to small single center reviews. De Blic et al 14 studied 34 patients with both claudication and critical limb ischemia treated with CFA PVI. Stenting was used in almost two-thirds of cases. Two patients required operative intervention, and four patients required reintervention. Primary patency at 1 year was 88% with a mean follow-up of 11 months.
14 These data are consistent with our findings. Another retrospective study of 53 patients with a mean follow-up of 2 years showed a freedom from restenosis rate of 92.5%. However, the rate of stent fracture was 9%. 15 A retrospective review of 115 patients showed a 90% technical success rate with a 6% perioperative complication rate including access site hematoma (1.7%) and thromboembolism (4.1%). 16 Thirty-day mortality and amputation rates were 2.5% and 0.8%. The 1-and 3-year reintervention-free survival rates were 77% and 57%. The 1-and 3-year amputation-free survival rates were 84% and 70%, respectively. 16 Overall, these periprocedural and long-term outcomes were less favorable than in our cohort of patients. Calligaro et al 17 looked at stent graft use in the CFA in 17
patients. The DFA was deliberately covered in one patient. 17 Reintervention rate was 11.8% at 2 years, and the secondary patency rate at 2 years was 100%. There were no major periprocedural complications. Stent grafts were not often used in our series and, as such, our overall numbers are likely too low to make any relevant conclusions. Dattilo acute limb ischemia (27%). The procedure was technically successful in 90% of cases and major complications occurred in two (7%) patients. There was no procedurerelated mortality. Life table estimates of survival and amputation-free survival at 1 year were both 96%. In those patients who had a successful revascularization, the overall 1-year estimate for primary and secondary patency was 88% and 92%. Historically common femoral endarterectomy has been viewed as a safe operation with good perioperative and long-term results. An analysis of isolated elective CFA endarterectomy in the American College of Surgeons National Surgical Quality Improvement Program showed a 30-day mortality rate of 1.5%. 13 This is very similar to the rate after PVI in our series. The most common perioperative complication was superficial surgical site infection (6.3%). Cardiac and pulmonary complications were 1% and 1.9%, respectively. At least one complication, including major and minor, was seen in 7.9% of the patients. High-risk patients for mortality were identified as those with functional dependence and dyspnea at rest. Independent predictors of morbidity included steroid use, diabetes mellitus, and obesity. 13 One retrospective single center review looking at short-and long-term outcomes examined 65 limbs in 58 patients. 12 The majority were for claudication (68%). More than one-half (57%) were hybrid iliac or femoropoliteal interventions. Technical success was achieved in 100% of the cases. Hemodynamic success was achieved in 95% of the cases as assessed by an increase in ankle-brachial index. Average hospital LOS was 3.2 days (range, 1-12 days), which is longer than the PVI LOS in our series. There were three (5%) major complications requiring reintervention. There were six (9%) minor complications, which were treated conservatively including wound infections and one lymph leak, and no perioperative mortality was observed. Primary patency at 1 and 5 years was 93% and 91%, respectively. Our cohort's primary patency at 1 year was 83%. Assisted primary patency was 100% at both time points. There was no difference in patencies between procedures performed alone or as a hybrid procedure. Freedom from reintervention in the ipsilateral limb was 82% at 1 year and 78% at 5 years and survival was 89% at 1 year and 70% at 5 years. Survival in our cohort was slightly higher with 92.9% at 1 year. There were no amputations.
12
Our results revealed a good perioperative safety profile for isolated DFA interventions; however, our numbers were too low to perform long-term analysis. DFA interventions added to CFA interventions did not influence outcomes. These patients had more comorbidities and were more likely to have previous intervention compared with the CFA only group. There is little published data about isolated DFA interventions. One retrospective analysis of isolated endovascular interventions noted a technical success rate of 94% that was similar to our cohort. 19 The 12-month amputation-free survival and reintervention-free survival rates were 78% and 72%, respectively. 24 There are a number of limitations to our analysis. First, it is a self-reported retrospective study. There is no specific data about where in the CFA the stents were placed in relation to the DFA. Also, the follow-up is limited. The low rate of follow-up in both groups is noteworthy and prohibits reliable analysis of long-term patency, freedom from amputation, major adverse limb events, and other major adverse and quality of life outcomes. Low followup within VQI reflects real world practice and is an area for further study and opportunity for quality improvement. Another limitation of this study is the lack of details for lesion characteristics, such as lesion length and percent stenosis. However, this is a limited space with much less variability regarding lesion length as in the superficial femoral artery, for example. Degree of calcification that may guide whether an atherectomy is performed or not is also missing. The VQI only lists the first two interventions perfumed. This would underreport a third treatment modality. It would be difficult to analyze this data based on treatment type apart from the primary and secondary treatment type. This makes in depth treatment type analysis in the VQI difficult. Overall, our numbers in the study, if divided by treatment type, would be too low for any meaningful analysis. We did incorporate primary and secondary treatment type into multivariate analysis however. VQI does not have a module for isolated common femoral endarterectomy, only listing cases associated with lower extremity bypass. This, unfortunately, makes direct comparison of PVI and endarterectomy not possible. Although ankle and toe to brachial indices are in the VQI, many of these values are missing. LOS is recorded from the index revascularization and does not reflect preadmission for foot surgery or drainage of sepsis. Also, although we were able to identify Rutherford 4 patients in the VQI dataset, we were unable to distinguish between Rutherford 5 or 6 presentation.
CONCLUSIONS
Endovascular interventions of the CFA and DFA have a low rate of perioperative morbidity and mortality. Oneyear patency is lower than historical controls of CFA endarterectomy. Stent use is associated with reintervention and amputation. Longer-term analysis is needed to better assess durability of these interventions. 
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